Purine derivatives as potent γ-secretase modulators

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 7, 2010, Pages 2279-2282

  Rivkin, Alexey ^a   Ahearn, Sean P ^a   Chichetti, Stephanie M ^a   Hamblett, Christopher L ^a   Garcia, Yudith ^a   Martinez, Michelle ^a   Hubbs, Jed L ^a   Reutershan, Michael H ^a   Daniels, Matthew H ^a   Siliphaivanh, Phieng ^a   Otte, Karin M ^a   Li, Chaomin ^a   Rosenau, Andrew ^a   Surdi, Laura M ^a   Jung, Joon ^a   Hughes, Bethany L ^a   Crispino, Jamie L ^a   Nikov, George N ^a   Middleton, Richard E ^a   Moxham, Christopher M ^a   Szewczak, Alexander A ^a   Shah, Sanjiv ^a   Moy, Lily Y ^a   Kenific, Candia M ^a   Tanga, Flobert ^a   Cruz, Jonathan C ^a   Andrade, Paula ^a   Angagaw, Minilik H ^a   Shomer, Nirah H ^a   Miller, Thomas ^a   Munoz, Benito ^a   Shearman, Mark S ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHOXYPHENYL PIPERAZINE; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; GAMMA SECRETASE; NOTCH RECEPTOR; PIPERAZINE DERIVATIVE; PURINE DERIVATIVE; PYRIMIDINE; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG POTENCY; HYDROGEN BOND; IN VITRO STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; STRUCTURE ACTIVITY RELATION; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; HUMANS; MICE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PURINES; RECEPTORS, NOTCH; STRUCTURE-ACTIVITY RELATIONSHIP;

MUS MUSCULUS;

EID: 77949490327     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.02.008     Document Type: Article

References (25)

1. Selkoe D. Physiol. Rev. 81 (2001) 741
2. Hardy J.A., and Higgins G.A. Science 256 (1992) 184
3. Golde T.E. J. Clin. Invest. 111 (2003) 1
4. Herbert L.E., Beckett L.A., Scherr P.A., and Evans D.A. Alzheimer Dis. Assoc. Disord. 15 (2001) 169
5. Griffiths H.H., Morten I., and Hooper N.M. Expert Opin. Ther. 12 (2008) 704
6. Cummings J.L. N. Engl. J. Med. 351 (2004) 56
7. Dickson D.W. J. Neuropathol. Exp. Neurol. 56 (1997) 321
8. Hardy J., and Selkoe D.J. Science 297 (2002) 353
9. Imbimbo B.P. Curr. Top. Med. Chem. 8 (2008) 54
10. Maillard I., Adler S.H., and Pear W.S. Immunity 19 (2003) 781
11. Stanger B.Z., Datar R., Murtaught L.C., and Melton D.A. Proc. Natl. Acad. Sci. U.S.A 102 (2005) 12443
12. Behr D. Curr. Top. Med. Chem. 8 (2008) 34
13. In't Veld B.A., Ruitenberg A., Hofman A., Launer L.J., Van Duijn C.M., Stijnen T., Breteler M.M.B., and Stricker B.H.C. N. Engl. J. Med. 345 (2001) 1515
14. Weggen S., Eriksen J.L., Das P., Sagi S.A., Wang R., Pietrzik C.U., Findlay K.A., Smith T.E., Murphy M.P., Butler T., Kang D.E., Marquez-Sterling N., Golde T.E., and Koo E.H. Nature 414 (2001) 212
15. Lim G.P., Yang F., Chu T., Chem P., Beech W., Teter B., Tran T., Ubeda O., Hsaio Ahse K., Reautschy S.A., and Cole G.M. J. Neurosci. 20 (2000) 5709
16. Peretto I., and La Porta E. Curr. Top. Med. Chem. 8 (2008) 38
17. Pissarnitski D. Curr. Opin. Drug Discovery Dev. 10 (2007) 392
18. Rivkin A., Ahearn S.P., Chichetti S.M., Kim Y.R., Li C., Rosenau A., Kattar S.D., Jung J., Shah S., Hughes B.L., Crispino J.L., Middleton R.E., Szewczak A.A., Munoz B., and Shearman M.S. Bioorg. Med. Chem. Lett. 20 (2010) 1269
19. Blurton, P.; Fletcher, S.; Teall, M.; Harrison, T.; Munoz, B.; Rivkin, A.; Hamblett, C.; Siliphaivanh, P.; Otte, K. WO 099210, 2008.
20. Rivkin, A.; Ahearn, S. P.; Chichetti, S. M.; Hamblett, C. L.; Garcia, Y.; Martinez, M.; Munoz, B. WO 019392, 2010.
21. 50 measurements for Aβ40 and Aβ42 were determined using AlphaLISA detection of peptides secreted by SH-SY5Y cells stably overexpressing the β-APP C-terminal fragment SPA4CT:. Bielefeld-Sevigny M. Assay Drug Dev. Technol. (2009) 90
22. Clarke E.E., and Shearman M.S. J. Neurosci. Methods 102 (2000) 61
23. Dyrks T., Dyrks E., Monning U., Urmoneit B., Turner J., and Beyreuther K. FEBS Lett. 335 (1993) 89
24. HeLa cells were made to co-express nonfunctional halves of luciferase, one fused to NotchΔE and the other to RBP-Jκ. γ-Secretase mediated cleavage of NotchΔE results in release of Notch intracellular domain (NICD)/N-terminal luciferase, which translocates to the nucleus and binds the RBP-Jκ/C-terminal luciferase to form a functional luciferase enzyme. This split-luciferase complementation system is used to detect NICD levels by measuring total luminescence upon addition of luciferin to lysed cells. Paulmurugan, R.; Gambhir, S. S. Anal. Chem. 2005, 77, 1295.
25. Lamb B.T., Sisodia S.S., Lawler A.M., Slunt H.H., Kitt C.A., Kearns W.G., Pearson P.L., Price D.L., and Gearhart J.D. Nat. Genet. 5 (1993) 22